Keywords: hopes, launch, cladribine, japan, johnson, through, its
J&J hopes to launch cladribine in Japan
Article | 08 April 2002
Johnson & Johnson, through its Japanese subsidiary JanssenPharmaceutical KK, plans to launch the cancer drug cladribine for the treatment of non-Hodgkin's ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
